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Abstract
Background: PTPH1 is a protein tyrosine phosphatase expressed in T cells but its effect on immune response is still 
controversial. PTPH1 dephosphorylates TCRzeta in vitro, inhibiting the downstream inflammatory signaling pathway, 
however no immunological phenotype has been detected in primary T cells derived from PTPH1-KO mice. The aim of 
the present study is to characterize PTPH1 phenotype in two in vivo inflammatory models and to give insights in 
possible PTPH1 functions in cytokine release.
Methods: We challenged PTPH1-KO mice with two potent immunomodulatory molecules, carrageenan and LPS, in 
order to determine PTPH1 possible role in inflammatory response in vivo. Cytokine release, inflammatory pain and gene 
expression were investigated in challenged PTPH1-WT and KO mice.
Results: The present study shows that carrageenan induces a trend of slightly increased spontaneous pain sensitivity 
in PTPH1-KO mice compared to WT (wild-type) littermates, but no differences in cytokine release, induced pain 
perception and cellular infiltration have been detected between the two genotypes in this mouse model. On the other 
hand, LPS-induced TNFα, MCP-1 and IL10 release was significantly reduced in PTPH1-KO plasma compared to WTs 30 
and 60 minutes post challenge. No cytokine release modulation was detectable 180 minutes post LPS challenge.
Conclusion: In conclusion, the present study points out a slight potential role for PTPH1 in spontaneous pain 
sensitivity and it indicates that this phosphatase might play a role in the positive regulation of the LPS-induced 
cytokines release in vivo, in contrast to previous reports indicating PTPH1 as potential negative regulator of immune 
response.
Background
Innate immunity is the early and relatively nonspecific
response to invading pathogens, activated via the Toll-
like and T-cell receptors, on antigen presenting cells and
on T cells, respectively [1,2]. The intensity and duration
of the immune response is under stringent regulation.
Tyrosine phosphorylation is a central mechanism in the
control of key signaling proteins involved in innate
immunity. The role of protein tyrosine kinases (PTKs)
has been widely studied but less is known on the protein
tyrosine phosphatases (PTPs) responsible for immuno-
regulation [3].
PTP action on immune response can be either positive
or negative, promoting or inhibiting the immune system.
SRC homology 2 (SH2)-containing tyrosine phosphatase-
2 (SHP-2) has a controversial effect on lymphocyte sig-
naling. Qu and colleagues demonstrated that SHP-2 is
essential for erythroid and myeloid cell differentiation [4],
and a missense mutation in the ptpn11 gene (encoding
for SHP-2 protein) is associated with various forms of
leukemia [5]. SHP-2 may also have an inhibitory role on
the activation of T and B lymphocytes [6]; SHP-2 can
hamper the TRIF (TIR-domain-containing adapter-
inducing interferon-β) adaptor protein-dependent TLR4
and TLR3 signal transduction with a consequent block of
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the pro-inflammatory cytokine production [7]. Another
negative regulator of hematopoietic cell development and
function is SHP-1 (SRC homology 2 (SH2)-containing
tyrosine phosphatase 1), that is mainly expressed in
hematopoietic and lymphoid cells [8]. Lymphocyte spe-
cific phosphatase, (LYP) and its mouse orthologue PEP
(PTP enriched in proline, glutamic acid, serine, and thre-
onine sequences) are predominantly expressed in leuko-
cytes and act as potent negative regulators of the TCR
signaling pathway [9]. A specific missense mutation in
the LYP encoding gene, ptpn22, has been associated in a
highly reproducible manner with autoimmune disease, as
type1 diabetes [10] and rheumatoid arthritis [11].
Another PTP involved in the immune processes is PTP-
MEG, a cytosolic phosphatase expressed in the thymus
that is able to dephosphorylates TCRζ ITAMs in vitro.
Trapping mutant experiments show that PTPMEG inac-
tivation leads to increased activation of the NF-kB path-
way [12]. However PTPMEG deletion in vivo does not
induce TCRζ ITAMs dephosphorylation, and PTPMEG-
KO mice do not show obviously altered immune
responses [12].
The present study is focused on PTPH1 (also known as
PTPN3), a cytosolic PTP that has been proposed to
inhibit TCR signaling. PTPH1 overexpression in Jurkat T
cells reduces indirectly the TCR-induced serine phospho-
rylation of Mek, Erk, Jnk and AP-1 leading to a decreased
IL-2 gene activation [13]. The indirect effect of PTPH1
could be mediated by the dephosphorylation of one or
several signaling components upstream of Mek and Jnk,
such as the TCR-associated protein tyrosine kinases
(PTK) or their immediate targets. Further studies will be
needed to identify the direct substrate for PTPH1. It has
been also demonstrated that the FERM (band 4.1, ezrin,
radixin, moesin) domain of PTPH1 is necessary for the
inhibition of Mek, Erk, Jnk and AP-1 and also for local-
ization of the phosphatase on the plasma membrane of
Jurkat T cells [14]. These studies corroborate the hypoth-
esis of a possible role for PTPH1 as negative regulator in
TCR signaling. Indeed, biochemical approaches and sub-
strate trapping experiments identify PTPH1, together
with SHP-1, as the phosphatases able to interact and to
dephosphorylate TCRζ in vitro [15]. A comparatively
recent ex vivo study on PTPH1-KO primary T cells failed
to show any significant role of this phosphatase in T cell
development and activation, thus excluding a possible
function for PTPH1 in the negative regulation of TCR
signaling [16]. This discrepancy between in vitro and ex
vivo data has been explained by a possible redundancy
effect of PTPMEG, that belongs to the same family pro-
tein of PTPH1. As already mentioned, PTPMEG is able to
dephosphorylate the TCR ITAMs and to regulate NF-κB
[12]. Despite the similarity in protein structure between
P T P M E G  a n d  P T P H 1 ,  n o  e v i d e n c e  c a n  s u p p o r t  t h e
hypothesis of PTPH1 affecting NF-κB pathway. However,
the double PTPH1-PTPMEG KO mouse line fails to show
a T ce ll phenotype, indica ting t ha t PTP MEG does not
compensate for the lack of PTPH1 action in primary T
cells [17].
In the present study, we examined the contribution of
PTPH1 to the regulation of inflammatory responses in
mice with a targeted deletion of PTPH1 gene expression.
PTPH1-KO and WT mice were treated with two potent
immunomodulatory molecules, carrageenan (CARR) and
lipopolysaccharide (LPS). Nociceptive perception and
cytokine expression and release have been investigated in
these two models of local (carrageenan) and systemic
(lipopolysaccharide) inflammation.
Methods
Animals
PTPH1-KO mice were generated as described in detail
elsewhere [18]. The experiments were performed on
adult female mice PTPH1-WT and KO individually
housed in top filter cages with free access to food and
water, under controlled temperature (21 ± 2°C), and rela-
tive humidity (55 ± 10%), on a 12:12 h light-dark cycle.
Protection of animals used in the experiment was in
accordance with Directive 86/609/EEC, enforced by the
Italian D.L. No. 116 of January 27, 1992. Physical facilities
and equipment for accommodation and care of animals
were in accordance with the provisions of EEC Council
Directive 86/609. Animals were allowed to acclimate for 1
week before the beginning of the experiments. All behav-
ioral tests were performed during the light phase and ani-
mals were allowed 1-hour habituation to the test room, if
different from the holding room, before testing. Testing
sequence was randomized between KO and WT animals,
and all apparatus were thoroughly cleaned between two
consecutive test sections.
Cytometric beads Array (CBA)
At the end of both inflammatory models, a panel of
cytokines was analyzed in blood. At sacrifice whole blood
was collected from the heart of the animals and plasma
was obtained by centrifugation. 25 μl of plasma were used
to quantify the levels of the circulating inflammatory
cytokines TNFα, MCP-1, IL-6, IL-10, IFN-γ, IL-12p70
using a mouse inflammation cytometric beads array kit
(BD Bioscience), according to the manufacturer's instruc-
t i o n s .  D a t a  w e r e  a c q u i r e d  w i t h  a  F A C S C a l i b u r  f l o w
cytometer and analyzed with BD CBA Software (BD Bio-
science).
Carrageenan-induced inflammation
Female PTPH1-KO and WT mice (3 months old) were
tested for inflammation-induced edema and hyperalge-
sia/allodynia. On the test day, n = 7-8 animals per geno-Patrignani et al. Journal of Inflammation 2010, 7:16
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type were injected subcutaneously in the right hind paw
plantar surface with 30 μL of a solution of 2% carra-
geenan λ (Sigma, Germany) freshly prepared in saline. 30
μL of saline were injected as control in the controlateral
paw. Animals were tested at automated Von Frey and
Hargreaves apparatus, to evaluate respectively tactile
allodynia and thermal hyperalgesia at 1, 3, 5 and 24 hours
after carrageenan/saline injection, followed by paw thick-
ness measurement, using a precision caliper (Mitutoyo,
Japan). Mice underwent also to a Catwalk analysis at the
same time points. Mice were sacrificed by an intraperito-
neal (ip) overdose of thiopental and paws were removed
for histological evaluation.
Hargreaves' plantar test
Thermal hyper/hypoalgesia was assessed by Hargreaves'
plantar apparatus (Plantar test, Ugo Basile, Italy) [19].
The test was performed at 1, 3, 5 and 24 hours after 2%
carrageenan injection. Animals were accustomed to the
apparatus for 1 hour for 2 days preceding the test. On the
test day, animals were individually placed in a clear
acrylic box on a glass platform and a removable infrared
generator (radiant heat 137 mW/cm2/s) was placed
underneath the animal's hind paw. The apparatus auto-
matically detected the withdrawal of the paw. Latency of
each paw withdrawal was recorded and mean values of
left and right paws were used as reaction index for the
individual animal. A cut-off of 25 seconds was used to
avoid tissue damage in case of absence of response.
Automated Von Frey test
Mechanical allodynia was assessed by a Dynamic Plantar
Aesthesiometer (Ugo Basile, Italy). The test was per-
formed immediately after the Hargreaves's test. Animals
were accustomed to the apparatus for 1 hour, for 2 days
proceeding the test day. On the test day, mice were indi-
vidually placed in a clear acrylic box with a grid floor. A
blunted probe was placed under the plantar surface of
one hind paw and automatically exerted a constantly
increasing force to the plantar surface (from 0 up to 5
grams over 20 s). Force applied (g) at the retraction reflex
was automatically recorded. Each hind paw was tested 3
times and mean values used as individual parameter for
group statistic.
CatWalk
Spontaneous pain was assessed using the CatWalk™ (Nol-
dus Information Technology) gait analysis method
[20,21]. Briefly, light from a fluorescent tube was sent
through a glass plate. Light rays were completely reflected
internally. As soon as the paw of the mouse was in con-
tact with the glass surface, light was reflected down-
wards. It resulted in a sharp image of a bright paw print.
The whole run was recorded by a camera placed under
the glass plate.
In the present study, the following parameters related
to single paw were analyzed:
• Duty cycle (expressed in %): the duty cycle represents
stance duration as a percentage of step cycle duration. It
is calculated according to the formula: stand duration/
(stand + swing phases duration) × 100, where the stand
phase is indicated as the time of contact (in seconds) of
one paw with the glass plate in a single step cycle and the
swing phase is indicated as seconds of non-contact with
the plate during a step cycle. The duty cycle parameter is
highly correlated with the Von Frey thresholds [22] and it
is used to assess pain-related spontaneous behavior in the
carrageenan-induced knee joint arthritis [23].
•  Print area (expressed in mm2): this parameter
describes the surface area of the complete paw print dur-
ing the stance phase.
Histological Analysis
At sacrifice paws were collected and placed in 4% forma-
lin. Paws were then incubated for 10-15 days in Shandon
TBD2 decalcifier (Thermo-Scientific) and subsequently
cut in 7 μm thick slices by a microtome. After mounting,
the slides were let overnight at 37°C, dehydrated and
stained with hematoxylin and eosin in a multiple steps
procedure. Histological evaluation was observed by
microscopy and described by an operator blind to the
genotypes.
LPS-induced inflammation
PTPH1-WT and KO female mice (n = 3-6, 2 months old)
received an ip injection of 1 mg/kg of LPS (Escherichia
coli 0127:B8, batch 032K4099, L3880, Sigma) and ran-
domized groups of mice were sacrificed by an ip overdose
of thiopental at 30, 60 and 180 minutes after LPS injec-
tion. The test was performed in three sessions with
equivalent group representation.
RTPCR on white cells
At the designed time points, blood was processed for RT-
PCR on white cells as follows. Red blood cells were lysed
from whole blood with BD PharM Lyse™ lysing solution
(BD Biosciences/BD Pharmingen) and whole white cells
were washed in PBS. RNA from whole white cells was
extracted using TriZol (Invitrogen). 200 ng of total RNA
were used to perform the RT-PCR reaction (SuperScript
II RT kit, Invitrogen). The qPCR experiment was carried
out using the Taqman Universal PCR master mix
(Applied Biosystems) on the following cytokine genes:
ccl2 (#Mm00441242_m1, Applied Biosystems), IL1b
(#Mm01336189_m1, Applied Biosystems), IL12a
(#Mm00434169_m1, Applied Biosystems), IL6
(#Mm00446190_m1, Applied Biosystems), TNF
(#Mm00443258_m1, Applied Biosystems). The compara-
tive Ct method [24] was used for data analysis, where:Patrignani et al. Journal of Inflammation 2010, 7:16
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and (delta)Ctsample is the Ct value for any sample nor-
malized to the endogenous housekeeping gene (beta-2-
microglobin, Applied Biosystems) and (delta)Ctreference is
the Ct value for matched PTPH1-WT vehicle treated
value, also normalized to the endogenous housekeeping
gene.
Statistical analysis
Statistical comparisons were performed by Two-way
Anova followed by T-test and Bonferroni's post-hoc anal-
ysis (p < 0.05) at each time points. Results are expressed
as mean ± SEM.
Results
Carrageenan (CARR)-induced inflammation
Female WT and KO mice were subcutaneously injected
in the right hind paw plantar surface with 2% carrageenan
λ freshly prepared in saline. 30 μL of saline were injected
as control in the controlateral paw. No major adverse
effects were observed after injection of 2% carrageenan in
the right paw of the mice. All the animals stayed alive
until the end of the experiment.
Cytometric Beads Array
Peripheral inflammatory responses to CARR were ana-
lyzed for six induced cytokines: TNFα, MCP-1, IL-6, IL-
10, IFN-γ, IL-12p70, using a CBA kit. CBA analysis was
performed on the plasma of control (n = 4 per genotype)
and 2% CARR-treated PTPH1-WT and KO female mice.
No significant cytokine modulation was detected in
healthy and treated WT and KO mice 24 hours after car-
rageenan injection (data not shown).
Paw thickness
Significantly increased paw thickness was measured by a
precision caliper in the CARR-treated paws, compared to
the controlateral vehicle treated ones (Figure 1). This
increment was statistically significant in both WT and
KO groups and was already detectable 1 hour after carra-
geenan injection. The edema was still present 24 hours
post-carrageenan injection (PTPH1-WT: P1h=0.0028;
P3h=0.0022; P1h=0.0049; P1h=0.0006) (PTPH1-KO:
P1h=0.0001; P3h=0.0002; P1h=0.0002; P1h=0.0003) (Figure
1). No statistical differences in paw thickness were
detected in PTPH1-WT versus PTPH1-KO animals.
Behavioral Tests
Hargreaves's test CARR-treated paws showed a signifi-
cant decrease in the Hargreaves'test response compared
to the controlateral vehicle treated ones (Figure 2a). This
reduced withdrawal time was statistically significant in
both WT and KO groups; it was detectable already at 1
hour after carrageenan injection through 24 h maintain-
ing the same intensity (PTPH1-WT: P1h=0.00004;
P3h=0.0122; P1h=0.0016; P1h=0.0039) (PTPH1-KO:
P1h=0.0001; P3h=0.00001; P1h=0.0005; P1h=0.0005) (Figure
2). No statistical differences in withdrawal time were
detected in PTPH1-WT versus PTPH1-KO animals (Fig-
ure 2a).
Von Frey test CARR injection also induced a signifi-
cantly decreased response at the Von Frey test compared
to the controlateral vehicle treated paw (Figure 2b).
Again, the reduction observed in mice undergoing this
test was statistically significant in both PTPH1-WT and
KO groups, already detectable at 1 hour after carrageenan
injection and maintained through 24 h with the same
intensity (PTPH1-WT:P1h=0.017; P3h=0.0002;
P1h=0.001621; P1h=0.002458) (PTPH1-KO: P1h=0.004;
P3h=0.00977; P1h=0.001272; P1h=0.007833) (Figure 2b).
No statistical differences in withdrawal force were
detected between the two genotypes.
CatWalk test Print area No differences in print area due
to either treatment or genotype were detectable at 1 and 3
hours post CARR-injection. At 5 and 24 hours post-injec-
tion, KO CARR-treated paws showed a significant
decreased print area compared to controlateral vehicle-
treated paws (PKO5 h < 0.05; PKO24 h < 0.05). No differences
w e r e  d e t e c t e d  i n  WT  CA R R - t r e a t e d  vs  vehicle-treated
paws at 5 hours post-injection, but a trend in decreased
print area was present in WT CARR-treated vs vehicle-
treated paws at 24 hours time point (P WT24 h = 0.0642)
(Figure 3a).
Duty cycle In the WT group, a slight significant decrease
in duty cycle was detectable in the CARR-treated paws
compared to the vehicle-treated ones, already 1 hour
after CARR-injection (PWT1 h < 0.05; Figure 3b). At this
time point, no significant differences were found within
the KO mice group (CARR vs vehicle treated animals) nor
between WT and KO mice. No differences in duty cycle
due either to treatment or to genotype were detectable at
3 hours post CARR-injection. At 5 hours post CARR-
injection, PTPH1-KO CARR-treated paws displayed a
significant decreased duty cycle compared to the contro-
lateral vehicle-treated one (PKO5 h < 0.01), but not com-
pared to the WT CARR-treated animals. This difference
was maintained in KO mice, CARR vs vehicle, also at 24
hours post-injection (PKO24 h < 0.05), and it was detectable
also in the WT mice group (CARR vs vehicle PWT24 h <
0.05) (Figure 3b).
Histological Analysis
Vehicle treatment did not induce any signs of inflamma-
tion in both PTPH1-WT and KO mice (data not shown).
Carrageenan treatment induced a moderate to severe
acute inflammation in the paws of both PTPH1-WT (Fig-
ure 4a-4c) and KO mice (Figure 4d-4f) compared to vehi-
() ()() () delta delta Ct delta Ct delta Ct sample reference =−Patrignani et al. Journal of Inflammation 2010, 7:16
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cle treatment 24 hours after challenge. Neutrophil
infiltration and hemorrhage, represented by red cell pres-
ence, were detected in CARR-treated mice 24 hours after
injection (Figure 4c, 4f). No genotype-related differences
were noted by simple visual observation in the paw archi-
tecture or in cellular infiltration at this late time point.
LPS-induced inflammation
Female mice (PTPH1-WT and KO) received an ip injec-
tion of 1 mg/kg of LPS and were sacrificed by an ip over-
dose of thiopental at 30, 60 and 180 minutes after LPS
injection. No major side or toxic effects were observed
after ip injection of LPS in PTPH1-WT and KO female
mice. All the animals stayed alive until the end of the
experiment. At sacrifice, blood was collected and plasma
and total white cell populations were isolated, as previ-
ously described. RT-PCR on white cells was performed
for cytokine genes.
RT-PCR on cytokine-related genes
RT-PCR was carried out for the following cytokine genes:
TNFα, ccl2 (MCP-1), IL12a, IL-1β, IL-6, IL-10 and IL-2.
TNFα gene expression levels were slightly increased in
white cells of LPS-treated mice compared to vehicle-
treated animals 30 minutes post treatment (mpt) in both
genotypes (Figure 5a).
At 60 mpt, TNFα mRNA levels of PTPH1-WT LPS-
treated mice were significantly higher (26 fold) compared
to vehicle-treated WTs (PWT 60 mpt < 0.05; Figure 5b). At
this time point, PTPH1-KO white cells displayed a trend
of increased TNFα mRNA levels (3.5 fold) in LPS-treated
vs  vehicle-treated mice (PKO 60 mpt = 0.42). Two-way
Anova analysis pointed out a genotype-related decrease
of TNFα gene expression (16.5 fold) in the LPS-treated
mice group, KO vs WT (PKOvsWT < 0.05; Figure 5b).
At 180 mpt, both PTPH1-WT and KO LPS-treated
mice showed a highly significant increase of TNFα
expression in whole white cells compared to vehicle-
treated animals (4.9 and 7.3 fold respectively) (PTPH1-
KO LPS vs vehicle; PKO 180 mpt < 0.001; PTPH1-WT LPS vs
vehicle; PWT 180 mpt < 0.01; Figure 5c). No genotype-related
differences in TNFα mRNA level were recorded at this
late time point.
Ccl2/MCP1 gene expression in white cells showed a
significant increase (187 fold) in WT LPS-treated com-
pared to vehicle-treated mice at 60 mpt (Figure 5d),
whereas no alteration was observed in KO mice or within
or between genotypes, at 30 (data not shown) and 180
minutes post treatment (Figure 5e).
IL1β, IL6, IL-10, IL-2 and IL12a expression levels were
not significantly altered in total white cells extracted from
LPS-treated vs vehicle-treated in both PTPH1-WT and
KO mice at any time point investigated (data not shown).
Figure 1 Carrageenan-induced paw edema in PTPH1-WT and KO mice. Paw edema was detectable at 1h after treatment in both genotypes at 
the same intensity. This increased thickness of the paws was maintained till sacrifice, at 24h post CARR-injection. No genotype-related differences were 
detectable between WT and KO CARR-treated groups. 2way Anova followed by Paired T-test  *:p<0.05; **:p<0.01; ***:p<0.001. V-WT: vehicle-treated 
PTPH1-WT mice; C-WT: CARR-treated PTPH1-WT mice; V-KO: vehicle-treated PTPH1-KO mice; C-KO: CARR-treated PTPH1-KO mice. 
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Cytometric Beads Array
Six cytokines (TNFα, MCP-1, IL-6, IL-10, IFN-γ, IL-
12p70) were analyzed in the plasma of LPS- and vehicle-
treated WT and KO mice. IFN-γ and IL-12p70 release
did not display a significant modulation in our mouse
model at the time points investigated. Values recorded
below detection limit were excluded from the final analy-
sis.
• 30 minutes post treatment TNFα overall release in the
plasma was increased in LPS-treated mice compared to
vehicle-treated ones 30 minutes post LPS injection (P2way
= 0.0199), but Bonferroni's post hoc test revealed no sig-
nificant differences in the PTPH1-WT and KO groups
associated with either treatment or genotype (Figure 6).
M C P - 1  l e v e l s  w e r e  s l i g h t l y  m o d u l a t e d  i n  W T  L P S -
treated plasma compared to the vehicle-treated group at
30 mpt, while no difference in the KO mice group was
d e t e c t a b l e  a t  t h i s  t i m e  p o i n t .  A  g e n o t y p e - r e l a t e d  5 0 %
decrease in MCP-1 release in plasma was recorded in
LPS-treated KO vs WT mice (PKOvsWT < 0.05).
IL10 levels in plasma were significantly increased due
to LPS treatment in WT mice at 30 minutes (165%, PWT <
0.05), whereas no difference in the KO mice group was
found. However, a genotype-related decrease in IL10
Figure 2 Behavioral tests performed on CARR-treated PTPH1-WT and KO mice. a) Withdrawal force measured at the Von Frey test was signifi-
cantly decreased by CARR treatment in both WT and KO mice, starting 1 hour after CARR injection, till 24 hours. The peak was reached 5 hours after 
CARR treatment. b) The withdrawal time measured at Hargreaves' test was significantly decreased by CARR treatment in both WT and KO mice, start-
ing 1 hour after CARR injection, till 24 hours. The peak of response was reached 5 hours after CARR treatment. No genotype-related differences were 
detectable between WT and KO CARR-treated groups at both tests. 2way Anova followed by Paired T-test *:p < 0.05; **:p < 0.01; ***:p < 0.001. V-WT: 
vehicle-treated PTPH1-WT mice; C-WT: CARR-treated PTPH1-WT mice; V-KO: vehicle-treated PTPH1-KO mice; C-KO: CARR-treated PTPH1-KO mice.
a
Hargreaves test
0.00
2.00
4.00
6.00
8.00
10.00
12.00
1 h 3h 5 h 24 h
w
i
t
h
d
r
a
w
a
l
t
i
m
e
 
(
s
)
***
*** ***
*** ***
* **
**
Von frey test 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
1 h 3 h 5 h 24 h
w
i
t
h
d
r
a
w
a
l
f
o
r
c
e
 
(
g
)
 
 
 
 
** ** ** ** ** ** ** *
V-WT
C- WT
V-KO
C- KO
V-WT
C- WT
V-KO
C- KO
bPatrignani et al. Journal of Inflammation 2010, 7:16
http://www.journal-inflammation.com/content/7/1/16
Page 7 of 14
release in plasma was detectable in LPS-treated KO vs
WT mice (150%, PKOvsWT < 0.05).
IL6 release was significantly higher in the plasma of
WT LPS-treated compared to vehicle-treated mice 30
minutes post LPS injection (PWT < 0.05), while no modu-
lation in IL6 levels was seen in KO mice, LPS vs vehicle.
No genotype-related differences in IL6 release were
detected in LPS- treated WT vs KO animals.
• 60 minutes post treatment At 60 minutes post LPS/
vehicle injection TNFα, MCP-1, IL-6 and IL-10 release
was highly significantly increased in the plasma of LPS-
treated animals compared to vehicle-treated mice in both
WT and KO groups (Figure 7). Moreover, a genotype-
related 50% decrease (PKOvsWT < 0.01) in TNFα, MCP-1
and IL-10 plasma level was seen in LPS-treated KO vs
WT mice (Figure 7). No genotype-related differences
were detected in IL-6 plasma release between PTPH1-
WT and KO animals (Figure 7).
• 180 minutes post treatment At 180 minutes post LPS/
vehicle challenge, TNFα (Figure 8a), MCP-1 and IL-6
(Figure 8b) levels were significant increased in the plasma
Figure 3 Catwalk analysis performed on CARR-treated PTPH1-WT and KO mice. a) The print area parameter was not modulated by CARR injec-
tion in both genotypes at 1 and 5 hours post-treatment; a slight CARR-induced decrease in print area was detectable in both genotypes at 5 and 24 
hours post-treatment and it was statistically significant only in KO mice group, at both time points. A trend in genotype-related difference between 
CARR-treated animals (WT and KO) was recorded 24 h after challenge. 2way Anova followed by Paired T-test *:p < 0.05; **:p < 0.01; ***:p < 0.001. b) 
The duty cycle parameter was significantly altered by CARR injection in WT mice 1 h post-treatment, but no difference was detected in KO mice group. 
No CARR-induced or genotype-induced differences in duty cycle were detectable 3 hours after CARR treatment. A slight CARR-induced decrease duty 
cycle was detectable in WT group at 5 hours post-treatment, while a strong down-regulation of this parameter was recorded in KO group. 24 hours 
after CARR treatment both genotypes displayed a decrease percentage of duty cycle and no genotype-related differences were detectable between 
WT and KO CARR-treated groups. 2way Anova followed by Paired T-test *:p < 0.05; **:p < 0.01; ***:p < 0.001.
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of WT and KO LPS-treated compared to vehicle-treated
mice, but no genotype-related differences were detect-
able. IL10 release was significantly increased in PTPH1-
KO LPS-treated mice vs their vehicle controls (Figure 8a)
(PKO < 0.05), while no modulation was recorded in WT
mice group. No genotype-related effect on IL10 release
was detectable between WT and KO mice.
Discussion
PTPH1 has been proposed to act as a negative TCR regu-
lator  in vitro, interacting and dephosphorylating the
TCRζ chain [13-15] but these results have not been con-
firmed by ex vivo studies on primary PTPH1-KO T cells
[16,17]. Therefore, we sought to ascertain whether
PTPH1 could have an effect on immune system upon
i n f l a m m a t o r y  c h a l l e n g e ,  t h u s  i n  t h e  c o m p l e x  in vivo
machinery. Two inflammatory mouse models were used
to test the impact of PTPH1 deletion on the immune sys-
tem: carrageenan- and LPS-induced inflammation.
Carrageenan λ is a sulfated polysaccharide derived
from red seaweed that is able to activate the innate
immune response. CARR interacts with TLR4 leading to
increased Bcl10, to NFκB pathway activation and IL8 pro-
duction [25,26]. CARR injection in the hind paw of the
mouse is one of the most commonly used models of
inflammation and inflammatory pain and it has a bipha-
sic profile [27]. Recent studies pointed out important
roles for prostaglandins, nitric oxide and TNFα in the
CARR-induced inflammatory response [27-29]. In partic-
ular , it has been shown that TNFα is involved in both
phases of mouse carrageenan-induced edema. Thus,
TNFα has a strong relevance not only in inflammatory
events, but also on nociceptive response and on neutro-
phil migration induced by carrageenan in mice [29]. Solu-
ble TNFα is processed from its pro-protein form by a
specific sheddase, called TACE [30,31], that is also
responsible for the processing of other cytokines and
cytokine receptors [32-35]. Interestingly, PTPH1 is
known to inhibit TACE expression and activity in vitro
[36]. We therefore analyzed cytokines plasma levels in
carrageenan-treated WT and KO mice, but no variation
was found between genotypes using this inflammatory
agent (data not shown), in agreement with a previous
CBA study on the rat carrageenan model [37]. We con-
clude that local 2% carrageenan stimulation might not be
sufficiently potent to unmask a phenotype in cytokine
modulation in PTPH1-KO mice at plasma level, and that
hind paw and muscle cytokine concentrations should be
analyzed in both genotypes, to unravel PTPH1 role in
local cytokine release.
As already mentioned, the CARR-induced model has a
biphasic profile, that is characterized by an early develop-
ment of edema, that peaks at 6 h and then again at 72 h
[27]. In the present study, carrageenan injection induced
paw edema in both PTPH1-WT and KO mice, detectable
already 1 hour after injection and persistent till 24 h (Fig-
ure 1), showing no differences in intensity between the
genotypes. Furthermore, carrageenan challenge induced
a marked neuthrophils migration to the site of injection
24 h after treatment (Figure 4) [27]. Another hallmark of
carrageenan stimulation is a long-lasting reduction in the
threshold to nociceptive stimuli, that was evident in our
Figure 4 H&E staining on PTPH1-WT and KO CARR-treated paws. a) PTPH1-WT paws 24 h after CARR treatment displayed a strong inflammation 
(4×), b) severe cellular infiltration (10×) and c) also red cells presence, indicating hemorrhage (40×). d) PTPH1-KO CARR-treated paws presented the 
same level of inflammation as matched WT paws (4×), e) with a strong presence of immune cells (10×) and f) red cells (40×).
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Figure 5 RT-PCR on white cells of LPS-treated WT and KO mice. Graphical representation of minus ΔΔCt values of WT LPS-treated, KO vehicle-
treated and KO LPS-treated calculated versus WT vehicle-treated. a) PTPH1- WT and KO mice displayed a trend in LPS-induced increased expression 
of TNFα in white cells 30 after treatment, that b) became significant 60 mpt in WT mice; at this time point also a genotype-related difference in TNFα 
expression was recorded between WT and KO mice; c) at 180 minutes TNFα levels were significantly increased by LPS in both WT and KO mice. d) 60 
minutes post challenge LPS-induced 187 fold increase in ccl2 gene expression in WT white cells was detected, and no difference in KO mice e) No 
difference was detected in ccl2 white cells expression of WT and KO mice, 180 minutes after LPS treatment. 2way Anova followed by T-test; *:p < 0.05; 
**:p < 0.01; ***:p < 0.001.
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Figure 6 CBA analysis on plasma 30 minutes after 1 mg/kg LPS injection. Genotype-related difference in MCP-1 and IL10 between WT and KO 
LPS-treated animals. WT animals displayed a LPS-induced increase in IL10 and IL6; dot line indicates the detection limit of CBA kit, as reported by the 
supplier. 2way Anova followed by Bonferroni post-hoc test; *:p < 0.05; **:p < 0.01; ***:p < 0.001.
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model already 1 h after challenge and was sustained for
up to 72 h [27,38,39]. PTPH1-KO mice did not show any
significant difference in neutrophils infiltration (Figure 4)
or in pain behavior both at V on Frey's and Hargreaves'
tests, compared to WT littermates (Figure 2a, 2b). These
findings suggest that PTPH1 does not play a major role in
the inflammatory-induced transmission and integration
of the allodynic and painful stimuli. Comparatively, Cat-
walk gait analysis showed a trend of slightly earlier onset
(5 h after injection) of spontaneous pain perception indi-
cated as print area (Figure 3a) and duty cycle (Figure 3b)
in PTPH1-KO mice, compared to matched WTs. Pilecka
and colleagues recently showed that PTPH1 is expressed
also in skeletal muscles [40]. Despite no differences were
detected in grip strength test between PTPH1-WT and
KO mice in basal condition (data not shown), Catwalk
data might also suggest a possible role of PTPH1 in mus-
cle fatigue. Further tests should be performed on PTPH1-
WT and KO mice upon challenge, in order to unravel the
underlying molecular mechanisms.
Carrageenan and LPS challenges are frequently used in
rodents as models to investigate innate immune response
mechanisms [41-43]. LPS is a major component of the
outer membrane of Gram-negative bacteria and it is a
critical player in the pathogenesis of septic shock [44].
Like carrageenan, LPS binds to the MD2-TLR4 complex
Figure 7 CBA analysis on plasma 60 minutes after 1 mg/kg LPS injection. Genotype-related difference detected in TNFα, MCP-1 and IL10 be-
tween WT and KO LPS-treated animals. Both WT and KO mice displayed a LPS-induced increase in TNFα, MCP-1 and IL10; IL6 level was significantly 
increased by LPS in both WT and KO mice. 2way Anova followed by Bonferroni post-hoc test; *:p < 0.05; **:p < 0.01; ***:p < 0.001.
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Figure 8 CBA analysis on plasma 180 minutes after 1 mg/kg LPS injection. a) PTPH1- WT and KO mice displayed a LPS-induced increase in TNFα 
and IL10; b) MCP-1 and IL6 levels were significantly increased by LPS in both WT and KO mice; dot line indicates the detection limit of CBA kit, as re-
ported by the supplier. 2way Anova followed by Bonferroni post-hoc test; *:p < 0.05; **:p < 0.01; ***:p < 0.001.
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and activates both MyD88-dependent and independent
(TRIF-dependent-TIR-domain-containing adapter-
inducing interferon-β) pathways [45-47]. The MyD88-
dependent pathway results in the activation of TRAF6
(TNF Receptor Associated Factor 6) and in the immedi-
ate activation of NFκ B, MAPK and JNK pathways, lead-
ing to the early production of pro-inflammatory
cytokines as TNFα, IL-1β, IL6 and MCP-1 [48-50].
MyD88-independent pathway results in rapid activation
of the interferon regulatory factors (IRF) 3 and 7 that
induces the production of IFNβ and consequently IFNα,
nitric oxide production and delayed NFκB activation
[48,50], leading to late cytokine production. LPS chal-
lenge on PTPH1-KO and WT mice aimed to understand
the possible role of this phosphatase in the inflammatory
process and in particular in cytokine expression and
release. Thus, CBA analysis was performed on the plasma
of LPS- and vehicle-treated WT and KO mice (IL-10, IL-
12p70, TNFα, IL-6, MCP-1, IFN-γ).
IL10 is an immunomodulatory cytokine, whose pro-
duction is rapidly induced by monocyte/macrophages
upon LPS challenge [51]. IL10 treatment in vitro is known
to negatively regulate LPS responses [51], in particular
inhibiting the induction of pro-inflammatory cytokines,
as TNFα, IL12 [52,53], IL-1α, and IL-6 [54,55]. Both
PTPH1-WT and KO mice displayed significantly
increased IL10 plasma level upon LPS challenge, but no
significant reductions of IL-6, TNFα and thus MCP-1
p l a s m a  l ev e l s  w e r e  d e t e c t e d  i n  L P S-t r e a t ed  vs vehicle-
treated PTPH1-WT and KO mice. Interestingly, IL10 lev-
els were reduced in LPS-treated KO mice plasma com-
pared to WTs, at 30 and 60 minutes after challenge
(Figure 6, 7); no increased MCP-1, TNFα, and IL6 plasma
levels were detected in LPS-treated KO vs WT mice at
these time points. Indeed, IL-10 has not an exclusive pro-
inflammatory action [56] and it has been demonstrated in
an LPS-model that IL-10 release increases as MCP-1, IL-
6 and TNFα [57]. Thus, our results on overall increased
cytokines levels upon LPS treatment are in accordance
with these studies. Comparatively, an overall decrease in
cytokines release was recorded at 30 and 60 minutes post
challenge in LPS-treated PTPH1-KO vs WT mice (Figure
6, 7).
Several studies reported that IL10 up-regulates the
expression of socs1 and socs3 genes, blocking the IFNs-
induced JAK/STAT pathway [51,58] and stimulating the
expression of PTP1B [51]. It has recently been demon-
strated that the production of IL10 by human Treg cells is
enhanced by IL2 signaling via activation of STAT5 mole-
cules [59,60]. PTPH1 is known to dephosphorylate
STAT5b in vitro [61], and therefore the IL10 reduction in
PTPH1-KO plasma after 30 minutes and 1 hour post LPS
injection appears counterintuitive (Figure 6, 7). These
data could indicate PTPH1 as a possible target of the
early MyD88-dependent pathway, which acts on the over-
all pro- and anti-inflammatory cytokines production, but
further investigations are needed to support this hypoth-
esis and to identify PTPH1 substrates.
LPS-induced IL6 release was detectable in WT mice,
LPS-treated vs vehicle-treated group, as reported by sev-
eral studies [62,63]. Increased IL6 plasma level of LPS vs
vehicle-treated mice were recorded also in KO mice, at
the three time points investigated. It has been recently
shown that JAK2 and STAT5 are required for LPS-
induced IL-6 production [63] and, as already mentioned,
STAT5b is known as PTPH1 substrate [61]. Thus, the
trend in decreased IL6 plasma levels of KO vs WT LPS
treated mice 60 minutes after challenge could be due to a
partial and temporally-limited inactivation of JAK/STAT
pathway by PTPH1 deletion. Further biochemical analy-
sis are necessary to confirm this hypothesis and to under-
stand the possible PTPH1 role in this pathway.
It has been widely demonstrated that endotoxin injec-
tion leads to a rapid and dose-dependent TNFα expres-
sion and release in mice [44,64,65]. The present study
demonstrates that LPS injection induced an increased
level of TNFα mRNA expression in LPS-treated vs vehi-
cle-treated mice in both PTPH1-WT and KO (Figure 5a,
5b, 5c), that is genotypically different only at 60 minutes
after endotoxin injection (Figure 5b). At this time point,
PTPH1-KO LPS-treated mice displayed lower TNFα
expression compared to matched WTs, that was detect-
able also at the level of TNFα release in plasma (Figure 7).
In particular, endotoxin injection led to a rapid and very
significant increase of TNFα release in both PTPH1-WT
and KO mice at the three time points investigated (Figure
7, 8). In accordance to mRNA level (Figure 5b), TNFα
release was significantly lower in LPS-treated KO vs
matched WT mice 60 minutes post challenge (Figure 7),
corroborating the hypothesis of a weaker inflammatory
response of PTPH1-lacking mice.
Furthermore, increased MCP-1 plasma levels were
recorded in both PTPH1-WT and KO LPS-treated vs
vehicle-treated mice (Figure 6, 7, 8). TNFα is known to
promote ccl2 gene expression [66,67], activating NFκB-
inducing kinases, including IκB kinases (IKK). IKKs pro-
mote NFκB heterodimers translocation into the nucleus,
leading to the transcription of targeted genes [66,67].
Several studies show that both NFκB and MAPK path-
ways are required for ccl2 induction; specifically, tran-
scription factor AP-1 contributes to TNFα-inducible
expression of MCP-1 gene [67-69]. This regulatory mech-
anism might explain the slight reduction of TNFα and
MCP-1 gene expression and release in KO mice 1 hour
post challenge (Table 1), when LPS induced the peak of
TNFα plasma levels. Indeed, LPS challenge failed to
induce a full response, as measured by TNFα expression
and release in PTPH1-KO mice, leading to a lower stimu-Patrignani et al. Journal of Inflammation 2010, 7:16
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lation of MCP-1 and possibly to a consequently reduced
monocytes and macrophages recruitment 1 hour after
injection. Cytokine levels in PTPH1-KO plasma were
comparable to WT 3 hours after LPS injection (Figure 8),
suggesting that PTPH1 activity was temporally limited at
t he peak of TNFα re lease, or t ha t some c om pensa t ory
mechanisms might have intervened later on, in the
inflammatory process.
Despite the fact that most pro-inflammatory cytokines
are transcribed after NFκB activation [68,70-72], the
overall control of production for several cytokines is
more complex, and includes other pathways as JAK/
STAT, MAPK [73,74], JNK [75,76] and also post-tran-
scriptional and post-translational regulatory steps within
these pathways, that could be cytokine-specific. PTPH1
could act at one or more steps of this composite regula-
tory process, by dephosphorylating key molecules, as
indicated by the lack of direct correlation between cytok-
ines expression and release, in particular for ccl2 (Table
1). Proteolytic conversion of pro-proteins into mature
cytokines is a further level of control for cytokine produc-
tion. TACE is involved in the ectodomain release of sev-
eral cytokines, in particular of membrane-bound TNFα
[30,77,78]. As already mentioned, PTPH1 has been
reported to be an inhibitor of TACE expression and activ-
ity in vitro [36], but the mechanism of this inhibition is
still unclear.
Conclusion
In summary, PTPH1-KO mice exhibit a trend of slight
increased spontaneous nociceptive perception in the
CARR-induced inflammatory pain model. A slight
decrease in TNFα expression and a significant overall
delayed cytokine release are detectable in PTPH1-KO
mice in the early phases of LPS-induced inflammation. In
conclusion, the present study highlights a slight potential
role for PTPH1 in spontaneous pain sensitivity and more
strikingly, it indicates that this phosphatase might play a
role in the positive regulation of the LPS-induced cytok-
ines release in vivo, in contrast to previous reports indi-
cating PTPH1 as potential negative regulator of immune
response [13-15].
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Table 1: Cytokine expression and release in LPS-treated mice- Summary
LPS-treated KO vs WT
Minutes post-injection
30 60 180
Cytokines Gene protein gene protein gene protein
TNFα ==- -==
MCP-1 =- -  ( n s ) -==
IL6 =-  ( n s )=-  ( n s )= =
IL12p70 =-====
IL 10 nn - nn - nn =
Summary of the CBA and RT-PCR results in LPS-treated PTPH1-WT and KO mice at different time points (30, 60 and 180 minutes post- 
injection). = indicates no variation between WT and KO LPS-treated mice; - indicates a lower expression/release in LPS-treated KO compared 
to WT matched ones; - (ns) indicates a trend in lower expression/release in LPS-treated KO compared to WT matched ones; nn indicates non-
performed.Patrignani et al. Journal of Inflammation 2010, 7:16
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